Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 CAD | -1.02% | -1.27% | -1.27% |
May. 09 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
Sales 2024 * | 58.06M 79.2M | Sales 2025 * | 64.72M 88.27M | Capitalization | 92.34M 126M |
---|---|---|---|---|---|
Net income 2024 * | -18M -24.55M | Net income 2025 * | -13M -17.73M | EV / Sales 2024 * | 1.59 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.43 x |
P/E ratio 2024 * |
-4.85
x | P/E ratio 2025 * |
-6.89
x | Employees | 91 |
Yield 2024 * |
5.04% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc.
1 day | -1.02% | ||
1 week | -1.27% | ||
Current month | -16.13% | ||
1 month | -21.21% | ||
3 months | -5.11% | ||
6 months | +5.98% | ||
Current year | -1.27% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 3.9 | -1.02% | 2,400 |
24-05-17 | 3.94 | -4.83% | 411 |
24-05-16 | 4.14 | +4.28% | 1,900 |
24-05-15 | 3.97 | +0.51% | 11,250 |
24-05-14 | 3.95 | +0.25% | 2,000 |
Delayed Quote Toronto S.E., May 21, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.27% | 92.31M | |
+19.31% | 73.31B | |
-4.75% | 23.98B | |
+4.89% | 8.8B | |
+9.21% | 8.6B | |
-20.79% | 8.07B | |
-1.41% | 4.16B | |
+12.27% | 4.14B | |
-2.75% | 3.88B | |
+23.24% | 3.72B |
- Stock Market
- Equities
- HLS Stock